title: Targeting mutant p53 through the mevalonate pathway.
abstract: It is well established that mutant forms of the p53 tumour suppressor acquire pro-oncogenic activities. Inhibition of the mevalonate pathway is now shown to promote degradation of select oncogenic mutant p53 proteins, indicating that destabilization of mutant p53 could be a promising therapeutic strategy.
authors: Dana Farber Cancer Institute, 450 Brookline Ave, Boston, Massachusetts 12215, USA.
authors: William
authors: W
authors: Freed-Pastor
authors: Department of Biological Sciences, Columbia University, New York, New York 10027, USA.
authors: Carol
authors: C
authors: Prives
mesh_terms: D000818:Animals; D017209:Apoptosis / Q000235:genetics*; D063646:Carcinogenesis / Q000235:genetics*; D006801:Humans; D008798:Mevalonic Acid / Q000378:metabolism*; D009154:Mutation / Q000235:genetics*; D009369:Neoplasms / Q000235:genetics / Q000378:metabolism*; D016159:Tumor Suppressor Protein p53 / Q000235:genetics* / Q000378:metabolism
chemical_list: D016159:Tumor Suppressor Protein p53; D008798:Mevalonic Acid